85 studies whose primary subject is MDMA were published in 2017, up from 71 in 2016. Newest first. Back to the MDMA overview
Oxford Scholarship Online December 21, 2017 Kélina Gotman
Choreomania became distinctly political. Missionary physicians and neuroscientists stationed in Madagascar and Brazil compared trance-like revolutionary uprisings to the literature on choreomania. Unlike earlier cases, however, these ‘movement disorders’, large-scale anti-colonial demonstrations characterized by shaking, frothing, falling, and visions—as well as, in Madagascar, ancestor...
Expert Review of Clinical Pharmacology December 17, 2017 Alexander M. Sherwood, Thomas E Prisinzano
Disrupted mental health affects up to one in three individuals globally and is an unmet medical challenge contributing to individual suffering as well as significant societal and economic burden [1...
December 5, 2017 H. Salem, T. Barton, Taha Ali et al.
ABSTRACT In recent years, ecstasy has become a very popular recreational drug. To date, very little data is available regarding its toxic side effects. Specifically, reports relating ecstasy use to the clinical diagnosis of leukoencephalopathy are quite rare. In this report, we present an interesting case of a 33-year-old female with a recent history of ecstasy abuse who presented with delirium...
European Journal of Clinical Pharmacology December 2, 2017 Patrick Vizeli, Henriette E. Meyer zu Schwabedissen, Matthias E. Liechti 15 citations
Methylenedioxymethamphetamine (MDMA, ecstasy) is used recreationally and frequently leads to sympathomimetic toxicity. MDMA produces cardiovascular and subjective stimulant effects that were shown to partially depend on the norepinephrine transporter (NET)-mediated release of norepinephrine and stimulation of α 1 -adrenergic receptors. Genetic variants, such as single-nucleotide polymorphisms...
Neurobiology of Learning and Memory December 2017 María Pilar García-pardo, Jose Enrique De la Rubia Ortí, Maria Asunción Aguilar Calpe
Drug addiction continues being a major public problem faced by modern societies with different social, health and legal consequences for the consumers. Consumption of psychostimulants, like cocaine or MDMA (known as ecstasy) are highly prevalent and cognitive and memory impairments have been related with the abuse of these drugs. The aim of this work was to review the most important data of the...
International Journal of Drug Policy December 2017 Marit Edland-Gryt, Sveinung Sandberg, Willy Pedersen
Ecstasy pills with MDMA as the main ingredient were introduced in many European countries in the 1980s, and were often linked to the rave and club scenes. However, use gradually levelled off, in part as a response to increased concerns about possible mental health consequences and fatalities. Extensive use of MDMA now seems to be re-emerging in many countries. In this study, we investigated the...
Psychiatric News November 30, 2017 Richard Karel
3,4-methylenedioxymethamphetamine (MDMA) holds promise to once again become a therapeutic tool. After 16 years of preliminary clinical trials, the Food and Drug Administration (FDA) in late August gave expedited approval for multiple phase 3 trials of 3,4-methylenedioxymethamphetamine (MDMA) as a potential "breakthrough therapy" for treatment of posttraumatic stress disorder (PTSD). The complex...
November 22, 2017 Martti Nissinen
Abstract The prophetic performance is typically associated with a specific state of mind variously called ecstasy, trance, or possession. This chapter demonstrates that an altered state of consciousness appears as a prerequisite of the prophetic performance in ancient Near Eastern, Greek, and biblical texts. One of the designations of Mesopotamian prophets, muḫḫûm/maḫḫû, implies an ecstatic...
The International Journal of Neuropsychopharmacology November 22, 2017 André Schmidt, Felix Müller, Patrick C. Dolder et al. 25 citations
Background: Stimulants such as methylphenidate and modafinil are frequently used as cognitive enhancers in healthy people, whereas 3,4-methylenedioxymethamphetamine (ecstasy) is proposed to enhance mood and empathy in healthy subjects. However, comparative data on the effects of methylphenidate and modafinil on negative emotions in healthy subjects have been partially missing. The aim of this...
International Journal of Drug Policy November 20, 2017 Jane Mounteney, Paul J Griffiths, Alessandra Bo et al.
This paper explores the recent resurgence in use of ecstasy/MDMA in Europe and highlights keys areas of continuity and divergence between the ecstasy market of the 1990s and the current MDMA market. Based on a scoping study involving a targeted multi-source data collection exercise on MDMA, it highlights nine areas that have undergone some level of change, linked with both supply and demand for...
Frontiers in Psychiatry November 20, 2017 Laura Orsolini, Gabriele Duccio Papanti, Domenico de Berardis et al. 99 citations
Hallucinogen-persisting perception disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects. HPPD was associated with a broader range of LSD (lysergic acid diethylamide)-like substances, cannabis, methylenedioxymethamphetamine (MDMA), psilocybin, mescaline, and psychostimulants. The recent emergence of novel...
Psychopharmacology November 20, 2017 Allison A. Feduccia, Julie Holland, Michael C Mithoefer 79 citations
Pharmacotherapy is often used to target symptoms of posttraumatic stress disorder (PTSD), but does not provide definitive treatment, and side effects of daily medication are often problematic. Trauma-focused psychotherapies are more likely than drug treatment to achieve PTSD remission, but have high dropout rates and ineffective for a large percentage of patients. Therefore, research into drugs...
Frontiers in Psychiatry November 17, 2017 Nikola Pinterová, Rachel R. Horsley, Tomáš Páleníček 37 citations
Objectives: Aminoindanes (“bath salts”, a class of novel psychoactive substances, NPSs) increased rapidly in popularity on the recreational drug market, particularly after mephedrone and other synthetic cathinones were banned in the UK in 2010. Novel aminoindanes continue to emerge, but relatively little is known about their effects and risks. Their history, chemistry, pharmacology, behavioural...
Psychopharmacology November 16, 2017 Eline Haijen, Magı́ Farré, Rafael de la Torre et al. 9 citations
Preclinical data have suggested involvement of the endocannabinoid (eCB) system in MDMA-induced memory impairment. Clinical research has shown that blockade of the 5-HT 2 receptor nulls memory impairment during MDMA intoxication. Interestingly, studies have demonstrated that the eCB and the 5-HT system interact. It was hypothesized that MDMA would cause an increase in eCB concentrations...
Trends in Psychiatry and Psychotherapy November 11, 2017 Lysa Remy, Juliana Nichterwitz Scherer, Luciano Santos Pinto Guimarães et al. 12 citations
Abstract Background This study examined drug use patterns and psychiatric symptoms of anxiety and depression among young Brazilian sexual minority ecstasy and LSD users and compared findings with those reported for their heterosexual peers. Method This cross-sectional study employed targeted sampling and ethnographic mapping approaches via face-to-face interviews conducted at bars and...
Mindfulness November 4, 2017 Sunjeev K. Kamboj, Ylva Walldén, Caroline J. Falconer et al. 27 citations
3,4-Methylenedioxymethylamphetamine (MDMA;'ecstasy') produces prosocial subjective effects that may extend to affiliative feelings towards the self. Behavioural techniques can produce similar self-directed affiliation. For example, compassionate imagery (CI) and ecstasy reduce self-criticism and increase self-compassion to a similar extent, with the effects of CI enhanced in the presence of...
Neurotoxicity Research November 2017 Giulia Costa, Micaela Morelli, Nicola Simola
The amphetamine-related drug 3,4-methylenedioxymethamphetamine (MDMA) is known to induce neurotoxic damage in dopaminergic regions of the mouse brain. In order to characterize how the number of administrations influenced the severity of MDMA-induced dopaminergic damage and to describe the localization and persistence of this damage, we evaluated the changes in tyrosine hydroxylase (TH) and...
Neuropharmacology October 6, 2017 D. Curry, M. B. Young, A‐nga T. Tran et al. 50 citations
ABSTRACT S,R(+/–)‐3,4‐methylenedioxymethamphetamine (SR‐MDMA) is an amphetamine derivative with prosocial and putative therapeutic effects. Ongoing clinical trials are investigating it as a treatment for post‐traumatic stress disorder (PTSD) and other conditions. However, its potential for adverse effects such as hyperthermia and neurotoxicity may limit its clinical viability. We investigated...
Metabolic Brain Disease October 2017 Azam Sajadi, Iraj Amiri, Alireza Gharebaghi et al.
3, 4-methylenedioxymethamphetamine (MDMA) or ecstasy is a derivative of amphetamine that leads to long term potentiation (LTP) disruption in the hippocampal dentate gyrus (DG). Exercise has been accepted as a treatment for the improvement of neurodegenerative disease. Herein, the effects of exercise on the MDMA- induced neurotoxicity were assessed. Male Wistar rats received intraperitoneal...
Cardiovascular toxicology October 2017 D A Fonseca, A F Guerra, F Carvalho et al.
3,4-Methylenedioxymethamphetamine (MDMA or "ecstasy") is a recreational drug used worldwide for its distinctive psychotropic effects. Although important cardiovascular effects, such as increased blood pressure and heart rate, have also been described, the vascular effects of MDMA and metabolites and their correlation with hyperthermia (major side effect of MDMA) are not yet fully understood and...